SCHEMBL3326299

SCHEMBL3326299

O=S(=O)(c1ccccc1OC(F)(F)F)n1ccc2cc(C3CNC3)ccc21

nearest known ligand 0.39

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 1/20 0.39
HTR6 P50406 11/20 0.39
CYP3A4 P08684 1/20 0.39
FABP4 P15090 2/20 0.38
AKR1C3 P42330 1/20 0.36
POLB P06746 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CHRM1 P11229 2/20 0.35
KDM2B Q8NHM5 1/20 0.35
RORC P51449 1/20 0.35
DRD3 P35462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tert-Butyl Formate SCHEMBL27795702 0.93 FGFR4 (0.37) FGFR4HTR6CYP3A4FABP4AKR1C3
SCHEMBL3327322 0.86 HTR6 (0.39) HTR6CYP3A4FABP4POLBL3MBTL1
SCHEMBL3325153 0.84 HTR6 (0.43) HTR6CYP3A4FABP4CHRM1DRD3
Hydrochloric Acid SCHEMBL3327844 0.83 HTR6 (0.42) HTR6CYP3A4FABP4CHRM1DRD3
SCHEMBL3325085 0.83 HTR6 (0.43) HTR6CYP3A4FABP4CHRM1DRD3
SCHEMBL27795700 0.82 FABP4 (0.40) FGFR4HTR6FABP4AKR1C3POLB
SCHEMBL3327854 0.81 HTR6 (0.42) FGFR4HTR6FABP4AKR1C3CHRM1
SCHEMBL3326162 0.81 HTR6 (0.46) FGFR4HTR6CYP3A4AKR1C3POLB
Tert-Butyl Formate SCHEMBL27774812 0.80 HTR6 (0.38) HTR6CYP3A4FABP4POLBL3MBTL1
SCHEMBL3328396 0.80 HTR6 (0.54) HTR6CYP3A4FABP4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507469-B2 Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor ABBOTT GMBH & CO. KG (DE) 2013-08-13 US claimed
US-20100137280-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2010-06-03 US claimed
US-8507469-B2 Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor ABBOTT GMBH & CO. KG (DE) 2013-08-13 US disclosed
US-20100137280-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137280-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR HTR6, HTR4, HTR3C FGFR4 1441/4885HTR6 1/4885CYP3A4 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.